Current Atherosclerosis Reports

, Volume 5, Issue 5, pp 418–422 | Cite as

Niacin: A powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events

  • Michael H. Davidson
Article

Abstract

Recent clinical trial data have demonstrated the benefits of utilizing niacin therapy in the management of dyslipidemia. In the Familial Atherosclerosis Treatment Study and the HDL Atherosclerosis Treatment Study (HATS), niacin combination therapy with a statin or resin resulted in significant reduction in cardiovascular events. The angiographic benefits in the HATS trial appear to be related to the change in large, high-density lipoprotein particle concentration, which is a prominent effect of niacin treatment. Recent evaluation in diabetic populations also has demonstrated a reduction in clinical events. Changes in hemoglobin Alc levels with niacin appear to be clinically insignificant and, therefore, the relative underutilization of niacin in diabetic patients is probably not warranted based on the most recent data.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kreisberg RA: Niacin: a therapeutic dilemma. “One man’s drink is another’s poison.” Am J Med 1994, 97:313–316.PubMedCrossRefGoogle Scholar
  2. 2.
    Guyton JR: Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1998, 82:18U-23U.PubMedCrossRefGoogle Scholar
  3. 3.
    Capuzzi DM, Guyton JR, Morgan JM, et al.: Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 82:74U–81U.Google Scholar
  4. 4.
    Jin FY, Kamanna VS, Kashyap ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997, 17:2020–2028.PubMedGoogle Scholar
  5. 5.
    Gray DR, Morgan T, Chretien SD, et al.: Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994, 121:252–258.PubMedGoogle Scholar
  6. 6.
    Bays H: Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol 2002, 90:30K-43K.PubMedCrossRefGoogle Scholar
  7. 7.
    Davidson MH: Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002, 90:50K-60K.PubMedCrossRefGoogle Scholar
  8. 8.
    Kashyap ML, McGovern ME, Berra K, et al.: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002, 89:672–678.PubMedCrossRefGoogle Scholar
  9. 9.
    Guyton JR, Goldberg AC, Kreisberg RA, et al.: Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998, 82:737–743.PubMedCrossRefGoogle Scholar
  10. 10.
    Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233–3240.PubMedCrossRefGoogle Scholar
  11. 11.
    Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360–381.CrossRefGoogle Scholar
  12. 12.
    Canner PL, Berge KG, Wenger NK, et al.: Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245–1255.PubMedCrossRefGoogle Scholar
  13. 13.
    Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298.PubMedCrossRefGoogle Scholar
  14. 14.
    Brown BG, Zhao X-Q, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.PubMedCrossRefGoogle Scholar
  15. 15.
    Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405–418.PubMedCrossRefGoogle Scholar
  16. 16.
    Morgan JM, Baksh RI, Stanton M, et al.: Beneficial effects of extended-release niacin on lipoprotein subclass distribution in patients with mixed dyslipidemia. Abstract presented at XIV Drugs Affecting Lipid Metabolism International Symposium. New York, New York; September 9–12, 2001.Google Scholar
  17. 17.
    Sakai T, Kamanna VS, Kashyap ML: Niacin, but not gemfibrozil, selectively increases Lp-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001, 21:1783–1789.PubMedGoogle Scholar
  18. 18.
    Asztalos BF, Batista M, Horvath KV, et al.: Change in {alpha} 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847–852.PubMedCrossRefGoogle Scholar
  19. 19.
    Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).JAMA 2001, 285:2486–2497.Google Scholar
  20. 20.
    Canner PL, Furberg CD, McGovern ME: Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from Coronary Drug Project [abstract]. Circulation 2002, 106:II-636.Google Scholar
  21. 21.
    Canner PL, Furberg CD, McGovern ME: Niacin decreases myocardial infarction and total mortality similarly in patients with and without metabolic syndrome [abstract]. J Am Coll Cardiol 2003, in press.Google Scholar
  22. 22.
    Grundy SM, Vega GL, McGovern ME, et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002, 162:1568–1576.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Michael H. Davidson
    • 1
  1. 1.Department of Preventive CardiologyRush-Presbyterian-St. Luke’s Medical CenterChicagoUSA

Personalised recommendations